Press "esc" to clear
Go to Advanced Search

Showing results

110 of 474
chinesewebsiteDanaFarber.jpg

Article ID: 698251

Dana-Farber Launches Chinese-Language Website

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute launches a new Chinese-language website.

Released:
2-Aug-2018 10:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 698300

After 60 Years, Scientists Uncover How Thalidomide Produced Birth Defects

Dana-Farber Cancer Institute

More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?

Released:
1-Aug-2018 12:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    18-Jul-2018 2:00 PM EDT

Article ID: 697439

Study Finds Melanoma Biomarkers Predicting Checkpoint Blocker Response

Dana-Farber Cancer Institute

Scientists at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.

Released:
17-Jul-2018 9:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    4-Jun-2018 9:35 AM EDT

Article ID: 695416

AI Plus Ovarian Suppression Yields Benefit in High-Risk Premenopausal Breast Cancer Patients

Dana-Farber Cancer Institute

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American Society of Clinical Oncology.

Released:
31-May-2018 3:30 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    2-Jun-2018 7:30 AM EDT

Article ID: 695424

Blood Test Shows Potential for Early Detection of Lung Cancer

Dana-Farber Cancer Institute

A test that analyzes free-floating DNA in the blood may be able to detect early-stage lung cancer, a preliminary report from the ongoing Circulating Cell-Free Genome Atlas (CCGA) study suggests.

Released:
31-May-2018 3:30 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 695359

Philips and Dana-Farber operationalize and scale Clinical Pathways

Dana-Farber Cancer Institute

he Dana-Farber Clinical Pathways will be deployed through the Philips IntelliSpace Oncology Platform, providing clinical decision support to physicians via a patient-centric solution.

Released:
31-May-2018 9:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    10-May-2018 4:00 PM EDT

Article ID: 693844

Study Reveals That Many Oncologists Recommend Medical Marijuana Clinically Despite Not Feeling Sufficiently Knowledgeable to Do So

Dana-Farber Cancer Institute

While a wide majority of oncologists do not feel informed enough about medical marijuana’s utility to make clinical recommendations, most do in fact conduct discussions on medical marijuana in the clinic and nearly half recommend it to their patients, say researchers who surveyed a population-based sample of medical oncologists.

Released:
1-May-2018 5:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    30-Apr-2018 11:00 AM EDT

Article ID: 693613

Genomic Analysis Unravels Complexities of the Most Common Form of Lymphoma and Enables Personalized Treatment

Dana-Farber Cancer Institute

The majority of patients with diffuse large B cell lymphoma (DLBCL) can be treated effectively. However, people whose disease recurs face a shortage of good options, especially because the disease is driven by a complicated mix of genetic alterations. Genomic analysis by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard now offers a better framework for understanding the disease’s many forms, which will help to predict individual patient outcomes and guide personalized treatment.

Released:
26-Apr-2018 5:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    27-Apr-2018 5:00 AM EDT

Article ID: 693609

In Multiple Myeloma, Different Types of Blood Biopsies Match Up Well with Bone Marrow Tests

Dana-Farber Cancer Institute

Bone marrow biopsies are the gold standard for diagnosing and monitoring the progression of multiple myeloma, but these procedures are far too invasive to perform at every patient visit. Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, however, have shown that two ways to measure multiple myeloma DNA in blood samples provide highly detailed sets of genetic information that agree well not just with each other but with results from bone marrow tests.

Released:
26-Apr-2018 4:15 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 690607

Dana-Farber’s Bank of Patient-Derived Tumor Xenografts Gets Major Boost From Novartis

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is establishing a bank of patient-derived xenograft models of more than 750 human tumors.

Released:
7-Mar-2018 5:00 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment

Showing results

110 of 474





Chat now!